ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades

Orexigen Financial Chief Cooper Resigns

DOW JONES NEWSWIRES Orexigen Therapeutics Inc. (OREX) said its chief financial officer is stepping down after four years as the biopharmaceutical company named a strategy executive to replace him on an interim basis. Financial chief and treasurer Graham Cooper resigned for personal reasons, the company said, after spending more than four years commuting to the job from the San Francisco Bay Area. Orexigen is based in San Diego. Cooper will remain in the post until the company reports its year-end results. Orexigen said it will name Jay Hagan, currently its senior vice president of corporate development and strategy, as acting CFO. Hagan joined the company in 2009 after 10 years at the biotech firm Amgen Inc. (AMGN). Orexigen is in a three-way race with Vivus Inc. (VVUS) and Arena Pharmaceuticals Inc. (ARNA) to bring the latest crop of diet pills to market, with Orexigen looking to advance its weight-loss drug Contrave. Coincidentally, Arena also disclosed the upcoming departure of its financial chief last week. Orexigen earlier this month cut 23 jobs, resulting in a 40% reduction of its work force, in the wake of a regulatory rejection of Contrave. Orexigen shares were up 2% to $3.47 in premarket trading. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909;;

Stock News for Arena (ARNA)
05/09/201617:50:49Quarterly Report (10-q)
05/09/201617:27:55Additional Proxy Soliciting Materials (definitive) (defa14a)
05/09/201617:14:44Current Report Filing (8-k)
05/09/201617:05:36Current Report Filing (8-k)
05/09/201616:05:00Arena Pharmaceuticals Reports First Quarter 2016 Financial Results...
05/09/201616:05:00Arena Pharmaceuticals Announces Appointment of Amit D. Munshi...
05/02/201616:05:00Arena Pharmaceuticals to Host First Quarter 2016 Financial Results...
04/28/201616:40:13Additional Proxy Soliciting Materials (definitive) (defa14a)
04/28/201616:22:41Proxy Statement (definitive) (def 14a)
04/12/201613:33:22Current Report Filing (8-k)
04/12/201608:00:00Arena Pharmaceuticals Reports Favorable Results from Phase 1b...
03/21/201606:07:19Current Report Filing (8-k)
03/04/201618:21:25Statement of Changes in Beneficial Ownership (4)
03/04/201618:19:54Statement of Changes in Beneficial Ownership (4)
03/04/201618:19:23Statement of Changes in Beneficial Ownership (4)
03/04/201618:17:39Statement of Changes in Beneficial Ownership (4)
03/04/201618:15:47Statement of Changes in Beneficial Ownership (4)
03/04/201618:14:18Statement of Changes in Beneficial Ownership (4)
02/29/201617:21:52Current Report Filing (8-k)
02/29/201616:00:00Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015...

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations